YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

UTHR | NASDAQ

$570.70 $28.81 | 5.32%

SIGNAL:

Signal available — unlock to view

|2026-07-13 |F&G 44 |RSI 71.9

Add to favoritesFavorite

Company Overview:

Market Cap: $23.08B

Trailing PE: 20.4x

FWD PE *: 21.9x

Payout Ratio (TTM): —

52-Week Range: $409.07 - $609.35

* Forward PE is based on street estimates.

10 Year UTHR Performance Metrics:

Total Return (with DRIP): 382.3% (17.04% CAGR)

Total Return (no DRIP): 382.3% (17.04% CAGR)

Share Price: 383.3% (17.06% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $48,225

Total Return $ (with DRIP): $38,225

UTHR Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

UTHR Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

UTHR Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

UTHR - Revenue

UTHR Revenue CAGR:1Y: -1.92%2Y: 4.67%5Y: 11.90%10Y: 6.62%

UTHR - Earnings Per Share (EPS)

UTHR EPS CAGR:1Y: 13.42%2Y: 11.48%5Y: 14.78%10Y: 5.17%

UTHR - Net Income

🔓 See the full chart40% off right now · 7-day free trial

UTHR Net Income CAGR:1Y: 7.59%2Y: 9.43%5Y: 14.05%10Y: 4.91%

UTHR - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

UTHR EBITDA CAGR:1Y: -14.01%2Y: 5.32%5Y: 9.75%10Y: 2.47%

UTHR - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

UTHR Free Cash Flow CAGR:1Y: 58.76%2Y: 4.83%5Y: 9.28%10Y: 5.95%

UTHR - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

UTHR Free Cash Flow / Share CAGR:1Y: 68.08%2Y: 7.02%5Y: 10.39%10Y: 6.37%

UTHR - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

UTHR Operating Income CAGR:1Y: -9.25%2Y: 1.69%5Y: 8.28%10Y: 1.49%

UTHR - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

UTHR Gross Profit CAGR:1Y: -3.83%2Y: 3.60%5Y: 0.00%10Y: 0.00%

UTHR - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

UTHR Shares Outstanding CAGR:1Y: -5.18%2Y: -1.81%5Y: -0.64%10Y: -0.24%

UTHR - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

UTHR Share Buybacks CAGR:1Y: 0.00%2Y: 126.12%5Y: 211.65%10Y: -8.08%

UTHR - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

UTHR Stock-Based Comp CAGR:1Y: 104.50%2Y: 24.71%5Y: 21.58%10Y: 48.32%

UTHR - Expenses

🔓 See the full chart40% off right now · 7-day free trial

UTHR Expenses CAGR:1Y: 73.63%2Y: 54.75%5Y: 45.96%10Y: 26.37%

UTHR - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

UTHR - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

UTHR - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

UTHR - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

UTHR - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

UTHR - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

UTHR - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

UTHR Revenue CAGR:1Y: -1.92%2Y: 4.67%5Y: 11.90%10Y: 6.62%

UTHR - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

UTHR Revenue CAGR:1Y: -1.92%2Y: 4.67%5Y: 11.90%10Y: 6.62%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

UTHR - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

UTHR Actual Revenue CAGR:1Y: -1.92%2Y: 4.67%5Y: 11.90%10Y: 6.62%

UTHR - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

UTHR Actual EPS CAGR:1Y: 13.42%2Y: 11.48%5Y: 14.78%10Y: 5.17%

UTHR - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

UTHR Actual Net Income CAGR:1Y: 7.59%2Y: 9.43%5Y: 14.05%10Y: 4.91%

UTHR - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

UTHR Actual EBITDA CAGR:1Y: -14.01%2Y: 5.32%5Y: 9.75%10Y: 2.47%

Ratios, Profit Margins & Return on Capital:

UTHR - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

UTHR Net Profit Margin CAGR:1Y: 9.67%2Y: 4.54%5Y: 1.92%10Y: -1.60%

UTHR - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

UTHR Gross Profit Margin CAGR:1Y: -1.94%2Y: -1.03%5Y: -0.97%10Y: -0.86%

UTHR - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

UTHR Price to Earnings CAGR:1Y: 65.41%2Y: 16.64%5Y: 8.27%10Y: 11.77%

UTHR - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

UTHR Price To Sales Ratio CAGR:1Y: 81.59%2Y: 21.96%5Y: 10.36%10Y: 9.99%

UTHR - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

UTHR Return on Capital Employed CAGR:1Y: 1.30%2Y: -4.02%5Y: 0.41%10Y: -10.36%

UTHR - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

UTHR Return on Invested Capital CAGR:1Y: 19.44%2Y: 5.97%5Y: 2.30%10Y: -8.87%

Projected Future Returns & Dividends for UTHR

Based on past 10-year performance, here are UTHR growth metrics:

Share price CAGR of +17.06%
Dividend CAGR of +0%

Using UTHR CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	UTHR (DRIP)	UTHR - No DRIP
Current Price	$570.70	$570.70
Start Shares	17.52	17.52
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	17.52	17.52
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$570.70	$570.70
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - UTHR

NOTE: Above numbers are our estimate based on UTHR's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

United Therapeutics Corporation (UTHR) had its IPO on 1999-06-17, and is traded on NASDAQ stock exchange.

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

UTHR website: https://www.unither.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — UTHR

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $570.70

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own UTHR? See every dividend it's paid you

Add your UTHR shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every UTHR dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

Add UTHR free →

Free plan · up to 5 holdings